Albumin/insulin

Drug Profile

Albumin/insulin

Alternative Names: Albulin; Albulin-G; Albumin/insulin fusion protein; Insulin analogue - Teva; Long-acting insulin - Teva

Latest Information Update: 14 Nov 2013

Price : $50

At a glance

  • Originator Human Genome Sciences
  • Developer Teva Pharmaceutical Industries
  • Class Antihyperglycaemics; Insulins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 14 Nov 2013 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (SC)
  • 14 Nov 2013 Discontinued - Phase-I for Type-1 diabetes mellitus in USA (SC)
  • 22 Feb 2008 CoGenesys has been acquired and merged into Teva Pharmaceutical Industries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top